Oppenheimer Analysts Increase Earnings Estimates for BioLineRx Ltd. (NASDAQ:BLRX)

BioLineRx Ltd. (NASDAQ:BLRXGet Rating) – Equities researchers at Oppenheimer lifted their FY2022 EPS estimates for BioLineRx in a note issued to investors on Tuesday, November 15th. Oppenheimer analyst M. Breidenbach now forecasts that the biotechnology company will post earnings per share of ($0.52) for the year, up from their previous estimate of ($0.56). The consensus estimate for BioLineRx’s current full-year earnings is ($0.53) per share. Oppenheimer also issued estimates for BioLineRx’s Q4 2022 earnings at ($0.12) EPS, Q1 2023 earnings at ($0.12) EPS, Q2 2023 earnings at ($0.12) EPS, Q3 2023 earnings at ($0.14) EPS, Q4 2023 earnings at ($0.12) EPS, FY2023 earnings at ($0.51) EPS, FY2024 earnings at ($0.44) EPS, FY2025 earnings at ($0.21) EPS and FY2026 earnings at ($0.07) EPS.

Separately, StockNews.com started coverage on BioLineRx in a research note on Wednesday, October 12th. They issued a “sell” rating on the stock.

BioLineRx Price Performance

NASDAQ BLRX opened at $0.68 on Friday. BioLineRx has a fifty-two week low of $0.57 and a fifty-two week high of $3.02. The stock’s 50-day moving average is $0.92 and its two-hundred day moving average is $1.25. The firm has a market cap of $41.84 million, a P/E ratio of -1.39 and a beta of 1.86. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.12 and a quick ratio of 4.58.

BioLineRx (NASDAQ:BLRXGet Rating) last released its quarterly earnings data on Tuesday, August 16th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02).

Institutional Investors Weigh In On BioLineRx

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Atria Wealth Solutions Inc. acquired a new position in shares of BioLineRx during the 1st quarter worth about $178,000. Renaissance Technologies LLC increased its position in BioLineRx by 377.6% in the 1st quarter. Renaissance Technologies LLC now owns 67,346 shares of the biotechnology company’s stock worth $115,000 after buying an additional 53,246 shares during the period. Armistice Capital LLC acquired a new position in shares of BioLineRx during the third quarter worth approximately $2,587,000. Altium Capital Management LP bought a new stake in shares of BioLineRx in the third quarter valued at approximately $3,838,000. Finally, Virtu Financial LLC grew its stake in shares of BioLineRx by 195.6% in the third quarter. Virtu Financial LLC now owns 46,168 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 30,551 shares during the last quarter. 2.22% of the stock is owned by institutional investors and hedge funds.

BioLineRx Company Profile

(Get Rating)

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.

Further Reading

Earnings History and Estimates for BioLineRx (NASDAQ:BLRX)

Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.